Regeneron to Present Updated Results of Linvoseltamab for Patients with Heavily Pre-treated Multiple Myeloma at ASCO 2023
- The updated results from 2 P-II expansion dose cohorts of the P-I/II trial evaluating linvoseltamab (BCMAxCD3 bispecific Ab). At recommended 200mg dose in the (LINKER-MM1) trial, the results showed impressive efficacy with rapid, deep & durable responses
- At a median follow-up of 6mos., ORR (71%), VGPR or better (59%) with 30% CR or sCR, the median time to onset of response was ≤1mos., probability of maintaining a response @6 & 12mos. (84% & 79%) & m-PFS (not reached)
- 54% were MRD- at 10-5 at 50 & 200mg who achieved CR or sCR with available MRD data, no new safety signals with longer follow-up in the P-I & II portions of the trial, AEs leading to treatment discontinuations (16%). The data from the trial will form the basis of planned regulatory submissions starting with the US FDA in 2023
Ref: Globenewswire | Image: Regeneron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.